NLRP3 and steatosis: Our study demonstrates that the intercellular communication between monocytes, hepatocytes and neutrophils is orchestrated by the NLRP3-IL-1β axis and therapeutic inhibition of NLRP3 in the early phase of MetALD prevents liver damage, inflammation and steatosis (Figure 6E).